New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...
In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...
Nektar Therapeutics Inc (NASDAQ:NKTR) stock is surging on Tuesday, with a session volume of 4.7 million compared to an average volume 239.7K as per data from Benzinga Pro. The company released ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback